KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Alnylam Pharmaceuticals (ALNY) Debt to Equity (2016 - 2025)

Alnylam Pharmaceuticals (ALNY) has disclosed Debt to Equity for 8 consecutive years, with $0.52 as the latest value for Q3 2025.

  • For Q3 2025, Debt to Equity changed N/A year-over-year to $0.52; the TTM value through Sep 2025 reached $0.52, changed N/A, while the annual FY2024 figure was $1.4, N/A changed from the prior year.
  • Debt to Equity hit $0.52 in Q3 2025 for Alnylam Pharmaceuticals, up from $0.48 in the prior quarter.
  • Across five years, Debt to Equity topped out at $1.4 in Q4 2024 and bottomed at $0.28 in Q1 2025.
  • Average Debt to Equity over 3 years is $0.76, with a median of $0.52 recorded in 2025.
  • On a YoY basis, Debt to Equity climbed as much as 510.32% in 2021 and fell as far as 510.32% in 2021.
  • Alnylam Pharmaceuticals' Debt to Equity stood at $1.15 in 2021, then grew by 21.69% to $1.4 in 2024, then crashed by 62.91% to $0.52 in 2025.
  • According to Business Quant data, Debt to Equity over the past three periods came in at $0.52, $0.48, and $0.28 for Q3 2025, Q2 2025, and Q1 2025 respectively.